文献速递心脑血管急症重症综合管理与镇静镇痛

危重症成人中2型单纯疱疹病毒脑炎:EURECA与Herpetics队列研究的回顾性分析

Herpes simplex virus type 2 encephalitis in critically ill adults: A retrospective analysis of EURECA and Herpetics cohort studies.
PubMed 文献 · Crit Care · 2026-03-13
一句话结论在285例重症单纯疱疹脑炎ICU患者中,HSV-2脑炎占6%,其临床表现与结局与HSV-1脑炎大体相当,提示无论基因型均应早期识别并标准化管理。

该研究对两个大型多中心队列中入住ICU的成人单纯疱疹脑炎(HSE)患者进行回顾性分析,按脑脊液HSV基因型分组,比较HSV-2与HSV-1脑炎的特征、管理与结局。285例HSE患者中17例(6%)为HSV-2脑炎,年龄60(53–67)岁,女性占58.8%。HSV-2组HIV感染比例显著更高(17.6% vs 1.5%,p<0.01),脑MRI异常比例更低(85.7% vs 97.7%,p=0.01),静脉阿昔洛韦疗程更短(18[4–21]天 vs 21[20–21]天,p=0.04)。3个月不良结局(改良Rankin量表评分3–6分)在HSV-2组为9/16(56.3%),HSV-1组为175/236(74.2%),差异无统计学显著(p=0.25)。作者认为HSV-2脑炎在重症HSE中占相当比例,临床表现为与结局与HSV-1大体相当,强调无论基因型均应早期识别并标准化管理。

要点

  • 在285例ICU单纯疱疹脑炎患者中,HSV-2脑炎占6%(17例),年龄60(53–67)岁,女性58.8%。
  • HSV-2组HIV感染比例显著高于HSV-1组(17.6% vs 1.5%,p<0.01),但免疫抑制状态比例两组差异无统计学显著(29.4% vs 15.4%,p=0.13)。
  • HSV-2组脑MRI异常比例显著低于HSV-1组(85.7% vs 97.7%,p=0.01),脑脊液检查结果两组相似。
  • HSV-2组静脉阿昔洛韦疗程短于HSV-1组(18[4–21]天 vs 21[20–21]天,p=0.04)。
  • 3个月不良结局(改良Rankin量表评分3–6分)HSV-2组9/16(56.3%) vs HSV-1组175/236(74.2%),差异无统计学显著(p=0.25)。

适用人群与场景

  • 两个大型多中心队列中入住ICU的成人单纯疱疹脑炎(HSE)患者,按脑脊液HSV基因型分为HSV-2组与HSV-1组。

处置流程与药物剂量

  • HSV-2脑炎患者接受静脉阿昔洛韦治疗,疗程18(4–21)天,短于HSV-1组的21(20–21)天(p=0.04)。

研究设计与关键结果

  • 研究类型为对两个大型多中心队列(EURECA与Herpetics)的回顾性分析;共285例HSE患者,其中HSV-2脑炎17例(6%),HSV-1脑炎为其余患者。
  • HSV-2组年龄60(53–67)岁,女性58.8%;免疫抑制状态比例两组差异无统计学显著(29.4% vs 15.4%,p=0.13);HIV感染比例HSV-2组显著更高(17.6% vs 1.5%,p<0.01)。
  • HSV-2组脑MRI异常比例显著低于HSV-1组(85.7% vs 97.7%,p=0.01),脑脊液检查结果两组相似。
  • 静脉阿昔洛韦疗程HSV-2组18(4–21)天 vs HSV-1组21(20–21)天,HSV-2组更短(p=0.04)。
  • 主要终点3个月不良结局(改良Rankin量表评分3–6分):HSV-2组9/16(56.3%) vs HSV-1组175/236(74.2%),p=0.25,差异无统计学显著。

证据类型、等级与局限

  • 证据类型:对两个大型多中心队列(EURECA与Herpetics)的回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,HSV-2脑炎在重症HSE中占相当比例,临床表现为与结局与HSV-1大体相当,强调无论基因型均应早期识别并标准化管理。
  • HSV-2脑炎患者中HIV感染比例显著更高(17.6% vs 1.5%,p<0.01),提示对该人群应关注HIV感染状态。
  • HSV-2脑炎脑MRI异常比例显著低于HSV-1(85.7% vs 97.7%,p=0.01),影像正常不能排除HSV-2脑炎。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Herpes simplex virus type 1 (HSV-1) is the leading cause of sporadic infectious encephalitis. Although typically associated with benign meningitis, HSV-2 can also cause encephalitis in adults, a condition that remains poorly characterized in intensive care unit (ICU). We aimed to compare the characteristics, management, and outcomes of critically ill adult with HSV-2 and HSV-1 encephalitis. METHODS: We performed a retrospective analysis of adults with herpes simplex encephalitis (HSE) admitted to the ICU in two large multicenter cohorts. Patients were classified according to cerebrospinal fluid (CSF) HSV genotype. The primary endpoint was unfavourable outcome at 3 months, defined as a modified Rankin Scale score 3–6. RESULTS: Among 285 HSE patients, 17 (6%) had HSV-2 encephalitis (age 60 [53–67] years, female sex 58.8%). Although the proportion of immunocompromised status did not differ significantly between groups (29.4% vs 15.4%, p = 0.13), HSV-2 cases had a significantly higher prevalence of HIV infection (17.6 vs 1.5%, p < 0.01), less frequent brain MRI abnormalities (85.7% vs 97.7%, p = 0.01) and similar CSF findings compared to HSV-1 cases. The duration of intravenous acyclovir treatment was shorter for HSV-2 cases (18 [4–21] days) versus 21[20–21] days, p = 0.04). Unfavourable outcome occurred in 9/16 (56.3%) patients with HSV-2 encephalitis and in 175/236 (74.2%) patients with HSV-1 encephalitis (p = 0.25). CONCLUSION: Encephalitis caused by HSV-2 represent a consistent proportion of severe HSE. Clinical presentation and outcomes and broadly comparable to those of HSV-1 cases, underscoring the importance of early recognition and standardized management of encephalitis caused by HSV, regardless of genotype.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Volpé T, Hassold N, de Montmollin E, et al. Herpes simplex virus type 2 encephalitis in critically ill adults: A retrospective analysis of EURECA and Herpetics cohort studies. Crit Care. 2026. PMID: 41826973. doi:10.1186/s13054-026-05865-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。